Claim being checked · Version 1 · Reviewed
“Forzinity is FDA-approved for a narrow Barth syndrome use.”
Written and source-checked by Anthony Treviso, founder of The Peptide Field.
No dosing advice. This guide explains research. It was not independently medically reviewed, and it does not diagnose, prescribe, or recommend treatment.
Supported with scope. The reviewed evidence supports this exact statement only in the situation described below.
Answer scope
This verdict checks the exact claim in the heading. It is not a universal grade for SS-31.
01 · Answer
Supported with scope
FDA granted accelerated approval for Forzinity to improve muscle strength in adults and children with Barth syndrome who weigh at least 30 kg. Accelerated approval uses an intermediate measure and requires a confirmatory study.
- What kind of evidence this is
- Regulatory or product record. This answer uses an official regulator record or a specific product label.
- What this answer covers
- The Forzinity label and FDA approval records as reviewed August 30, 2026. This answer covers only the named molecule and finished product. It also covers the product form and how people used it. The study limits include who took part, what was used for comparison, what changed, and how long the study lasted.
- Question type
- Approval and status. Whether a specific product has an approval or another official status.
02 · Sources
Read the sources behind this answer
01FDA grants accelerated approval to Forzinity for Barth syndromeU.S. Food and Drug Administration · Regulatory · 2025
Supports the scoped claim02Forzinity prescribing informationU.S. Food and Drug Administration · Drug label · 2025
Supports the scoped claim03Forzinity FDA approval letterU.S. Food and Drug Administration · Regulatory · 2025
Supports the scoped claim
Supports the scoped claim02Forzinity prescribing informationU.S. Food and Drug Administration · Drug label · 2025
Supports the scoped claim03Forzinity FDA approval letterU.S. Food and Drug Administration · Regulatory · 2025
Supports the scoped claim
- Editorial review
- Internal editorial review recorded
- Source review
- Anthony Treviso · Founder and responsible editor
- Medical review status
- Not independently medically reviewed. Editorial source review does not replace medical review.